Browse studies

Find your next paid study

6 recruiting studies matching your filters

A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cispl…

Locally Advanced Cervical AdenocarcinomaLocally Advanced Cervical Adenosquamous CarcinomaLocally Advanced Cervical Squamous Cell Carcinoma+5 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07061977

Phase 1

A Phase 1 Dose-Escalation and Expansion Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EVOLVE104 in Subjects With Advanced Urothelial and Squamous Cell Carcinomas

The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have …

Bladder CancerSquamous Cell Carcinoma of the LungEsophageal Squamous Cell Carcinoma+8 more

Estimated

~$10 – $8,750

EvolveImmune United, IncNCT07217171

Phase 1

A Prospective Cohort Study of Integrating Radiotherapy Into Chemotherapy With Pembrolizumab and Bevacizumab in Newly Diagnosed Stage IVB Cervical Cancer

This phase I/II trial tests the safety and effectiveness of receiving external beam radiation therapy (EBRT) and brachytherapy along with chemotherapy, consist…

Cervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma+1 more

Estimated

~$10 – $6,250

Jonsson Comprehensive Cancer CenterNCT06543576

Phase 1

A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the reco…

Cervical Squamous Cell CarcinomaSquamous Non-small-cell Lung CancerColorectal Cancer+2 more

Estimated

~$10 – $8,750

Alentis Therapeutics AGNCT07169734

Phase 1

A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+Squamous Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the reco…

Squamous Non-small-cell Lung CancerHead and Neck Squamous Cell CarcinomaCervical Squamous Cell Carcinoma+1 more

Estimated

~$10 – $8,750

Alentis Therapeutics AGNCT06747585

Phase 2

A Phase II Open-Label, Single Arm Pilot Study to Evaluate the Safety and Efficacy of Pembrolizumab for High-Grade Cervical Intraepithelial Neoplasia

This phase II trial studies the effect of pembrolizumab on cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab,…

Cervical Intraepithelial NeoplasiaCervical Squamous Cell Carcinoma In SituCervical Squamous Intraepithelial Neoplasia 2

Estimated

~$10 – $6,250

Jonsson Comprehensive Cancer CenterNCT04712851